<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01201018</url>
  </required_header>
  <id_info>
    <org_study_id>OS-DRS-P1-01</org_study_id>
    <nct_id>NCT01201018</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment</brief_title>
  <official_title>A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment - A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oshadi Drug Administration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oshadi Drug Administration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be non randomized, open label, dose rising study in cancer patients. Cancer&#xD;
      treatment is consisting of 2 different drugs: Oshadi D and Oshadi R that will be administered&#xD;
      orally.&#xD;
&#xD;
      The study will include two sessions:&#xD;
&#xD;
        -  A single dose period to evaluate acute toxicity of each drug&#xD;
&#xD;
        -  Consecutive multiple increment dose escalation period of both drugs to determine the&#xD;
           long-term safety, and the anticancer activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, serious adverse events occurrence</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified &quot;Response Evaluation Criteria in Solid Tumors&quot; (RECIST, Appendix 3) will be used.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Tumor</condition>
  <condition>Cancer</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>Oshadi DR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oshadi D, Oshadi R</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Oshadi DR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/ cytological proven solid tumor that is metastatic.&#xD;
&#xD;
          -  Age &gt; 21 years old.&#xD;
&#xD;
          -  ECOG Performance status &lt; 2.&#xD;
&#xD;
          -  Documented progressive metastatic disease according to RECIST criteria.&#xD;
&#xD;
          -  At least one lesion not within prior radiation field that is measurable per RECIST.&#xD;
&#xD;
          -  Primary tumor must have been resected.&#xD;
&#xD;
          -  Four weeks must elapse from prior therapy.&#xD;
&#xD;
          -  Patient has recovered to CTCAE &lt; Grade 1 from toxicities related to previous treatment&#xD;
             (except non-clinically significant AEs).&#xD;
&#xD;
          -  Patient must have adequate organ function.&#xD;
&#xD;
          -  Sexually active fertile patients and their partners must agree to use medically&#xD;
             accepted methods of contraception during therapy and 3 months after the last dose of&#xD;
             the study drugs.&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative pregnancy test at&#xD;
             screening.&#xD;
&#xD;
          -  Patient must understand and be willing to give written informed consent prior to any&#xD;
             study procedures or evaluations and be willing to adhere to all study schedules and&#xD;
             requirements.&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled Intercurrent illness or any history of significant cardiac, renal,&#xD;
             neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic&#xD;
             hepatic disease or any other disease which in the judgment of the investigator would&#xD;
             interfere with the study or confound the results.&#xD;
&#xD;
          -  Current or history of hematologic malignancies.&#xD;
&#xD;
          -  Patient with positive HIV serology at screening.&#xD;
&#xD;
          -  Female patient who are breastfeeding or have a positive pregnancy test at screening or&#xD;
             at any time during the study.&#xD;
&#xD;
          -  Radiation therapy &lt; 4 weeks prior to screening.&#xD;
&#xD;
          -  Patient has received any other type of investigational agent &lt; 4 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  Metastatic brain or meningeal disease.&#xD;
&#xD;
          -  Patient has prothrombin time/International Normalization Ration (PT/INR) or partial&#xD;
             thromboplastin time (PTT) test results &gt; 1.3 UNL.&#xD;
&#xD;
          -  Significant swallowing disorders.&#xD;
&#xD;
          -  Small bowel surgery.&#xD;
&#xD;
          -  Pelvic or abdominal radiation.&#xD;
&#xD;
          -  Pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical&#xD;
             situation which could affect oral absorption.&#xD;
&#xD;
          -  Evidence of concurrent (&lt; 5 years) second malignancy other than basal cell carcinoma&#xD;
             of the skin or cervical carcinoma in situ.&#xD;
&#xD;
          -  Mental disorders.&#xD;
&#xD;
          -  Inability to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avishai Sella, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zrifin Beer-Yaakov</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>September 12, 2010</study_first_submitted>
  <study_first_submitted_qc>September 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2010</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor</keyword>
  <keyword>cancer</keyword>
  <keyword>metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

